Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
13
4
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.7%
1 terminated/withdrawn out of 13 trials
85.7%
-0.8% vs industry average
54%
7 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Role: collaborator
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Role: collaborator
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Role: collaborator
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
Role: collaborator
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
Role: collaborator
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Role: collaborator
Improving Emergency Department Testing for Deep Vein Thrombosis
Role: collaborator
TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
Role: collaborator
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Role: collaborator
Adjust-Unlikely PE
Role: collaborator
VTE Prevention Following Total Hip and Knee Arthroplasty
Role: collaborator
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
Role: collaborator
Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Role: collaborator
All 13 trials loaded